und hier nochmal die Bestätigung der geleisteten Zahlungen an PTN :
"Under the terms of the Palatin License Agreement, in February 2017 we paid Palatin $60.0 million as a one-time upfront payment and will reimburse Palatin up to an aggregate amount of $25.0 million for all reasonable, documented, out-of-pocket expenses incurred by Palatin in connection with the development and regulatory activities necessary to submit a new drug application in the U.S. for bremelanotide for the treatment of HSDD in pre-menopausal women. The $60.0 million upfront payment made in February 2017 to Palatin was recorded as in-process research and development expense as the product candidate had not received regulatory approval."
Quelle = May 03, 2017 10-Q Quarterly report which provides a continuing view of a company's financial position
|
Thread abonnieren
ETF-Sparplan